- Home
- ABVX
ABVX
Abivax SA American
as of 12-03-2025 2:52pm EST
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.
| Founded: | 2013 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 9.6B | IPO Year: | N/A |
| Target Price: | $112.83 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.77 - $130.25 | Next Earning Date: | 08-11-2025 |
| Revenue: | $7,073,400 | Revenue Growth: | -33.90% |
| Revenue Growth (this year): | 6.8% | Revenue Growth (next year): | -29.35% |
AI-Powered ABVX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare ABVX vs Leading Stocks
See how ABVX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ABVX Abivax SA American - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.